Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy

Stopped early

Conditions studied: Malignant Neoplasm

In brief

This trial studies how well cardiac biomarkers work in the early detection of cardiotoxicity in patients receiving sunitinib malate or sorafenib chemotherapy. Some chemotherapies are known to cause damage to heart muscle cells, resulting in heart failure. Often, the damage is not detected until heart failure has already occurred. Testing for cardiac biomarkers, such as troponin I and/or T and B-type natriuretic peptide (BNP), may be useful in detecting heart damage earlier than other tests currently performed (such as echocardiogram and electrocardiogram).

Key facts

Study ID

NCT00532064

Run by

M.D. Anderson Cancer Center

People needed

55

Starts

2007-09-12

Expected to finish

2018-05-02

Last updated by the study team

2020-01-22

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient age 18-85 years
• Starting a new course of chemotherapy at MD Anderson Cancer Center that includes sunitinib or sorafenib
• Has a life expectancy of greater than 6 months

You may not qualify if…

• Unstable angina within the last 3 months
• Myocardial infarction within the last 3 months
• Left ventricular ejection fraction (LVEF) less than 40%
• Decompensated heart failure (HF) in the last 3 months

Where it is running

• M D Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.